Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Bosco

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
The Journal of Clinical Investigation|December 13, 2006
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancerEmily E Bosco, Ying Wang, Huan Xu, et al.
The Journal of Clinical Investigation|June 3, 2025
Immune cells promote paralytic disease in mice infected with enterovirus D68Mikal A Woods Acevedo, Jie Lan, Sarah Maya, et al.
Chemistry & Biology|February 28, 2012
Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammationEmily E Bosco, Sachin Kumar, Filippo Marchioni, et al.
Cancer Research|June 3, 2005
Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidyChristopher N Mayhew, Emily E Bosco, Sejal R Fox, et al.
Biomacromolecules|May 17, 2025
Intracellular Nanodelivery of DNA with Enzyme-Degradable and pH-Responsive Peptide DendronsM A Urello, H J Vaughan, L T Dockery, et al.
Oncogene|April 25, 2007
Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune functionM P Markey, J Bergseid, E E Bosco, et al.
Oncotarget|May 26, 2018
Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancerEmily E Bosco, R James Christie, Rosa Carrasco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal CancersAllison M Barrett, Zachary T Britton, Rosa A Carrasco, et al.
The Journal of Clinical Investigation|November 15, 2023
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancerPeter Zanvit, Dewald van Dyk, Christine Fazenbaker, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
The Journal of Clinical Investigation|December 13, 2006
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancerEmily E Bosco, Ying Wang, Huan Xu, et al.
The Journal of Clinical Investigation|June 3, 2025
Immune cells promote paralytic disease in mice infected with enterovirus D68Mikal A Woods Acevedo, Jie Lan, Sarah Maya, et al.
Chemistry & Biology|February 28, 2012
Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammationEmily E Bosco, Sachin Kumar, Filippo Marchioni, et al.
Cancer Research|June 3, 2005
Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidyChristopher N Mayhew, Emily E Bosco, Sejal R Fox, et al.
Biomacromolecules|May 17, 2025
Intracellular Nanodelivery of DNA with Enzyme-Degradable and pH-Responsive Peptide DendronsM A Urello, H J Vaughan, L T Dockery, et al.
Oncogene|April 25, 2007
Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune functionM P Markey, J Bergseid, E E Bosco, et al.
Oncotarget|May 26, 2018
Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancerEmily E Bosco, R James Christie, Rosa Carrasco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal CancersAllison M Barrett, Zachary T Britton, Rosa A Carrasco, et al.
The Journal of Clinical Investigation|November 15, 2023
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancerPeter Zanvit, Dewald van Dyk, Christine Fazenbaker, et al.
Pageof 6